Claims for Patent: 6,103,890

Summary for Patent: 6,103,890

Title:	Enzymatic nucleic acids that cleave C-fos
Abstract:	Enzymatic nucleic acid molecules which cleave c-fos RNA.
Inventor(s):	Jarvis; Thale (Boulder, CO), McSwiggen; James A. (Boulder, CO), Stinchcomb; Dan T. (Ft. Collins, CO)
Assignee:	Ribozyme Pharmaceuticals, Inc. (Boulder, CO)
Application Number:	08/998,099
Patent Claims:	1. An enzymatic nucleic acid molecule which specifically cleaves RNA encoded by a c-fos gene, wherein said enzymatic nucleic acid molecule is in a hairpin motif. 2. An enzymatic nucleic acid molecule which specifically cleaves RNA encoded by a c-fos gene, wherein said enzymatic nucleic acid molecule is in a hammerhead motif, wherein the binding arms of said enzymatic nucleic acid molecule comprise sequences complementary to any of sequences defined as SEQ. ID. NOS. 1-140. 3. The enzymatic nucleic acid molecule of claim 2, wherein said enzymatic nucleic acid molecule comprises a stem II region of length greater than or equal to 2 base pairs. 4. The enzymatic nucleic acid molecule of claim 1, wherein said hairpin motif consists essentially of any sequence selected from the sequences defined as SEQ. ID. NOS. 281-324. 5. The enzymatic nucleic acid molecule of claim 1, wherein the binding arms of said enzymatic nucleic acid molecule comprise sequences complementary to any of sequences defined as SEQ. ID. NOS. 325-368. 6. An enzymatic nucleic acid molecule which specifically cleaves RNA encoded by a c-fos gene, wherein said enzymatic nucleic acid molecule is in a hepatitis delta virus, VS nucleic acid, group I intron, Group II intron, or RNase P nucleic acid motif. 7. The enzymatic nucleic acid molecule of any of claims 1, 2, or 6, wherein said nucleic acid comprises between 12 and 100 bases complementary to said RNA. 8. The enzymatic nucleic acid molecule of any of claims 1, 2, or 6, wherein said enzymatic nucleic acid molecule comprises between 14 and 24 bases complementary to said RNA encoded by the c-fos gene. 9. The enzymatic nucleic acid molecule of claim 2, wherein said hammerhead motif consists essentially of any sequence selected from the sequences defined as SEQ. ID NOS. 141-280. 10. A mammalian cell including an enzymatic nucleic acid molecule of any one of any of claims 1, 2, or 6, wherein said mammalina cell is not a living human. 11. The mammallian cell of claim 10, wherein said cell is a human cell. 12. An expression vector comprising nucleic acid sequence encoding at least one of the enzymatic nucleic acid molecule of any of claims 1, 2, or 6, in a manner which allows expression of that enzymatic nucleic acid molecule. 13. A mammalian cell including an expression vector of claim 12, wherein said mammalian cell is not a living human. 14. The mammalian cell of claim 13, wherein said mammalian cell is a human cell. 15. The enzymatic nucleic acid molecule of claim 2, wherein said enzymatic nucleic acid molecule comprises: at least five ribose residues; phosphorothioate linkages on at least three of the 5' terminal nucleotides; a 2'-C-allyl modification at position No. 4 of said enzymatic nucleic acid; at least ten 2'-O-methyl modifications; and a 3'-end modification. 16. The enzymatic nucleic acid molecule of claim 15, wherein said 3'-end modification is a 3'-3'linked inverted deoxyribose moiety. 17. The enzymatic nucleic acid molecule of claim 2, wherein said enzymatic nucleic acid molecule comprises: at least five ribose residues; phosphorothioate linkages on at least three of the 5' terminal nucleotides; a 2'-amino modification at position No. 4, or at position No. 7 or at position No. 4 and position No. 7 of said enzymatic nucleic acid molecule; at least ten 2'-O-methyl modifications; and a 3'-end modification. 18. The enzymatic nucleic acid molecule of claim 2, wherein said enzymatic nucleic acid molecule comprises: at least five ribose residues; phosphorothioate linkages on at least three of the 5' terminal nucleotides; an abasic substitution position No. 4, or at position No. 7 or at position No. 4 and position No. 7 of said enzymatic nucleic acid molecule; at least ten 2'-O-methyl modifications; and a 3'-end modification. 19. The enzymatic nucleic acid molecule of claim 2, wherein said enzymatic nucleic acid molecule comprises: at least five ribose residues; phosphorothioate linkages on at least three of the 5' terminal nucleotides; a 6-methyl uridine substitution at position No. 4, or at position No. 7 or at position No. 4 and position No. 7 of said enzymatic nucleic acid molecule; at least ten 2'-O-methyl modifications; and a 3'-end modification.

Details for Patent 6,103,890

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2014-05-18
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2014-05-18
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2014-05-18